Background
The aim of our study was to compare the efficacy and safety of: 1) transarterial chemolipiodolization with gelatin sponge embolization vs chemolipiodolization without embolization, and 2) chemolipiodolization with triple chemotherapeutic agents vs epirubicin alone.
Methods
A single-blind, three parallel arm, randomized trial was conducted at three clinical centers with patients with biopsy-confirmed unresectable hepatocellular carcinoma. Arm 1 received triple-drug chemolipiodolization and sponge embolization, whereas Arm 2 received triple-drug chemolipiodolization only. Patients in arm 3 were treated with single-drug chemolipiodolization and sponge embolization. We compared overall survival and time to progression. Event-time distributions were estimated by the Kaplan-Meier method. All statistical tests were two-sided.
Results
From July 2007 to November 2009, 365 patients (Arm 1: n = 122; Arm 2: n = 121; Arm 3: n = 122) were recruited. The median tumor size was 10.9 cm (range = 7-22 cm), and 34.5% had macrovascular invasion. The median survivals and time to progression in Arm 1, Arm 2, and Arm 3 were 10.5 and 3.6 months, 10.1 and 3.1 months, and 5.9 and 3.1 months, respectively. Survival was statistically significantly better in Arm 1 than in Arm 3 (P < .001), whereas there was no statistically significant difference between Arm 1 and Arm 2 (P = .20). Objective response rates were 45.9%, 29.7%, and 18.9% for Arm 1, Arm 2, and Arm 3, respectively.
Conclusions
Chemolipiodolization played an important role in transarterial chemoembolization, and the choice of chemotherapy regimen may largely affect survival outcomes. However, the removal of embolization from chemoembolization might not statistically significantly decrease survival.
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Transarterial chemoembolization (TACE) is the most widely used palliative treatment for hepatocellular carcinoma (HCC) patients (1) . The advantage of TACE over supportive care has been reported in two randomized controlled trials (2, 3) . Classic TACE is composed of chemolipiodolization (local delivery of chemotherapy agents emulsified with lipiodol) and embolization. In theory, chemolipiodolization and embolization have synergistic antitumor effects: the former causes high intratumoral concentrations of cytotoxic drugs, and the latter cuts off blood supply to the tumor.
However, this theory has been challenged by many clinicians because there is no convincing evidence to clarify the mechanism by which TACE improves patient survival. Some think chemolipiodolization plays a major role and embolization might do more harm than good. Therefore, embolization should not be used to maintain long-term arterial patency, and the treatment sessions should be repeated at 3 week intervals (4-10).
Conversely, others believe that embolization plays a key role and chemolipiodolization has no effect but leads to side effects. Therefore complete embolization should be administered in the initial treatment, and chemotherapy should be limited to reduce toxic effects (11) (12) (13) (14) (15) . As a result, TACE protocols, including regimens, delivery methods, and treatment intervals, vary among global medical centers, and there is no doubt that some of these protocols are not as effective as others (16) . Therefore, we performed a trial to compare the safety and efficacy of 1) TACE with gelatin sponge embolization vs chemolipiodolization without embolization and 2) TACE with multiple chemotherapeutic agents vs a single agent alone. Three transarterial regimens were studied: triple-drug chemolipiodolization with embolization, triple-drug chemolipiodolization without embolization, and single-drug chemolipiodolization with embolization. The first regimen was selected as the reference arm.
We used epirubicin as the single-agent chemotherapy regimen. The most common chemotherapeutic drug used for TACE is doxorubicin/epirubicin, followed by cisplatin and mitomycin. However, a number of chemotherapeutic agents have been used, and controversy exists about the selection of the most appropriate drug (16) . We used epirubicin, lobaplatin (a third-generation platinum analogue), and mitomycin as a triple-agent chemotherapy regimen. Cisplatin was replaced by lobaplatin because the latter has been reported to have reduced toxicity, a better therapeutic index, and much higher solubility (17) (18) (19) . In this study, we used fixed-dose chemotherapy, and the dose was based on previous studies (16, 20) .
Methods

Patients and Study Design
We undertook a multicenter, single-blind, randomized, parallel group clinical trial between July 2007 and November 2010 in three medical centers in southern China. The study was approved by the institutional review board at each center and complied with the provisions of the Declaration of Helsinki. All patients provided written informed consent before enrollment in the study. The study has been registered at http://ClinicalTrials.gov (No. NCT00493402).
Patients with histologically confirmed HCC with unresectable disease without extrahepatic metastases were assessed for eligibility ( Figure 1 ). The Barcelona Clinic Liver Cancer (BCLC) system and Cancer of the Liver Italian Program classifications were used for staging (1, 21) . Eligibility criteria also included: 1) age between 18 and 75 years; 2) main tumor size greater than 7 cm; 3) HCC with no previous treatment; 4) adequate hematologic function (platelet count: >60 × 10 9 platelets/L; hemoglobin: >8.5 g/L; and prothrombin time: <3 seconds above control); 5) normal liver or Child-Pugh A liver cirrhosis with adequate hepatic function (albumin: ≥3.5 g/L; total bilirubin: ≤1.5 mg/L; and alanine aminotransferase and aspartate aminotransferase: ≤5 × upper limit of normal); 6) adequate renal function (serum creatinine: ≤1.5 × upper limit of normal); and 7) Eastern Co-operative Group performance status of zero or one (22) . Patients were excluded from the study if they had one or more of the following: 1) a hypovascular tumor (defined as a tumor with all its parts less contrast-enhanced than the nontumorous liver parenchyma on arterial phase computed tomography scans); 2) diffuse-type HCC; 3) evidence of hepatic decompensation including esophageal or gastric variceal bleeding or hepatic encephalopathy; 4) severe underlying cardiac or renal diseases; 5) color Doppler ultrasonography showing portal vein tumor thrombosis with complete main portal vein obstruction without cavernous transformation; or 6) obstructive jaundice. The patients remained blinded to the TACE regimen received. During the TACE procedure, a radiation shield encased in a sterile towel was placed between the patient's eyes and the operator. The attending staff was instructed not to reveal the identity of the TACE regimen to the patient.
Randomization and TACE Procedure
The interval from pretreatment evaluation to random assignment was limited to no more than 2 weeks. TACE was performed using the techniques we have described previously (23) . In brief, depending on size, location, and arterial supply to the tumor, the tip of the catheter was advanced into the segmental artery or specific tumor-feeding artery. After that, patients were randomly allocated to a treatment group by opening a sealed envelope containing their randomly assigned treatment group. The computer-generated randomization sequence was created by an independent organization with a 1:1:1 allocation, and was stratified by three centers, BCLC stage (stage B vs stage C), and tumor size (≤10 cm vs >10 cm). For two centers, the random block size for each stratum was 9 and 18. For the third center, where the subject recruitment rate was expected to be lower, the random block size for each stratum was 6 and 12. The three treatment groups were as follows:
1. Arm 1 received triple-drug chemolipiodolization with embolization. Lobaplatin (50 mg), epirubicin (50 mg), and mitomycin C (6 mg) were mixed in 9 mL of water-soluble contrast medium and 1 mL of sterile water for injection. The mixture was thoroughly mixed with 10 mL of lipiodol. After injection of the emulsion, 20 mL of pure lipiodol were injected. The injection was stopped either at the point of near stasis within the main artery feeding the tumor or after the entire amount of the above agent was administered. The actual volume administered was recorded. After that, embolization was performed with injection of gelatin-sponge particles 500 to 1000 μm in diameter through the catheter to reach stasis in the tumor-feeding artery. 2. Arm 2 received triple-drug chemolipiodolization without embolization. Chemolipiodolization was performed with the same combined regimen without gelatin-sponge embolization. 3. Arm 3 received single-drug chemolipiodolization with embolization. Treatment was the same as for Arm 1, except that only a single-drug, epirubicin (50 mg), was used.
Study Endpoint
The primary endpoint was the comparison of overall survival among the different treatment arms. After inclusion of the last patient in the study, a follow-up period of 12 months was scheduled. Follow-up ended on December 1, 2010. The secondary outcome was the time to radiological progression (TTP), which was defined as the time from random assignment to disease progression.
Statistical Analysis
For comparisons of baseline variables, the Student's t test for continuous variables and the χ 2 test for categorical variables were used. Treatment response and survival time were determined on an intent-to-treat basis. The survival curves and univariable analysis were calculated by the Kaplan-Meier method and compared using a log-rank test. Any factors that were statistically significant at P less than .10 in the univariate analysis were candidates for entry into a multivariable Cox proportional hazards model, the results of which are presented for the last step of the reverse selection of random variables. The proportional hazard assumption was checked by graphical inspection of the linearity of the hazards over time and log−log plots and by plotting Schoenfeld residuals over time. P values less than .05 were considered statistically significant. All statistical tests were two-sided. We analyzed the data for differences by sex but did not analyze ethnicity data. All statistical processing was performed by the Statistical Package for Social Science version 13.0 (SPSS Inc., Chicago, IL).
results
Patient Characteristics
From July 2007 to November 2009, 381 patients were registered for the study; 16 (4.2%) patients were excluded because the TACE procedure could not be accomplished (Figure 1 ). In total, 122, 121, and 122 patients were allocated to Arm 1, Arm 2, and Arm 3, respectively. The data from these patients were included in all subsequent analyses. The median tumor size was 10.9 cm (range = 7-22 cm). One patient in Arm 1, two patients in Arm 2, and one patient in Arm 3 were lost to follow-up. One patient in Arm 2 died in a traffic accident. Their data were censored at the time of their last followup visit (12.7, 5.2, 22.6, 17.1, and 22.5 months after randomization, respectively). Table 1 shows the baseline characteristics of all recruited HCC patients. The only difference between arms was that Arm 2 had fewer patients with positive hepatitis B surface antigen (P = .02).
Treatment Administration
Among all 365 patients, a mean of 1.61 study TACE sessions (range = 1-6 sessions; total = 592 sessions) was performed. There was no statistically significant difference in lipiodol administered in each TACE session among the three arms (21.6 ± 8.2 ml in Arm 1, 20.3 ± 7.0 ml in Arm 2, 19.4 ± 6.6 ml in Arm 3; P = .06). The study TACE sessions and subsequent treatments administered in each arm are listed in Table 2 . There was no statistically significant difference in the number of study treatment sessions among the three arms (Arm 1 vs Arm 2: P = .88; Arm 1 vs Arm 3: P = .11), and there was also no statistically significant difference in the number of subsequent treatment sessions between Arm 1 and Arm 2 (P = .11). There was, however, a statistically significant difference in the number of subsequent treatment sessions between Arm 1 and Arm 3 (P = .009).
Mortality and Morbidity
One patient in Arm 3 died of bleeding caused by tumor rupture on day 2 after first TACE. Another patient in Arm 1 died of irreversible liver failure on day 14 after second TACE. The in-hospital mortality rate was 0.3%, and the 1-month mortality rate was 0.3%. The average length of stay in hospitals after every study TACE session in Arm 1, Arm 2, and Arm 3 was 6.1 (range = 3-30) days, 5.6 (range = 2-21) days, and 5.7 (range = 2-21) days, and there was no statistically significant different between Arm 1 and Arm 2 (P = .11) or Arm 1 and Arm 3 (P = .30). Twenty-two (18.0%), 16 (13.2%), and 12 (9.8%) patients experienced adverse events of at least grade 3 in Arm 1, Arm 2, and Arm 3, respectively. There was no statistically significant difference in the severe adverse event rate between Arm 1 and Arm 2 (P = .22) or between Arm1 and Arm 3(P = .10). Table 3 shows the incidence of complications.
Tumor Response
The tumor response among patients in the study is shown in Table 4 . Objective response rates were 45.9%, 29.7%, and 18.9% for Arm 1, Arm 2, and Arm 3, respectively.
Time to Progression
Eighty-two patients (n = 33 patients in Arm 1, n = 24 patients in Arm 2, and n = 25 patients in Arm 3, respectively) who could not be evaluated for TTP because their tumor was removed by resection or ablation or becaseu of death, poor performance, or patients' refusal of further computed tomography scans. These patients were excluded from the analysis of TTP. The median TTP was 3.6 months (95% confidence interval [CI] = 2.4 to 4.8), 3.1 months (95% CI = 1.6 to 4.5), and 3.1 months (95% CI = 2.0 to 4.2) in Arm 1, Arm 2, and Arm 3, respectively. In univariable analysis, there was no statistically significant difference in TTP between Arm 1 and Arm 2 (P = .43), whereas the TTP was statistically significantly longer in Arm 1 than in Arm 3 (P = .03). However, in Cox multivariable analysis model, there was no statistically significantly difference in TTP among these three arms (Table 4) .
Survival Outcomes (Intention-to-Treat Analysis)
At the time of analysis, the median survival time was 8.4 months (range = 1-40 months), and 295 patients had died, including 97 patients in Arm 1, 94 patients in Arm 2, and 104 patients in Arm 3. For all 365 recruited patients, their overall survival at 6 months, 1 year, and 2 years was 63.2%, 38.6%, and 22.7 %, respectively. The median survivals in Arm 1, Arm 2, and Arm 3 were 10.5, 10.1, and 3.1 months, respectively. Survival was statistically significantly better in Arm 1 than in Arm 3 (P < .001), whereas there was no statistically significant difference between the two arms treated with triple-drug chemolipiodolization with or without embolization (Arm 1 vs Arm 2: P = .20) (Table 4 ; Figure 2 ). The analysis stratified according to the BCLC stage (stage B vs stage C) is shown in Figure 3 . In both stage B and stage C HCC patients, Arm 1 had statistically significantly improved survival outcomes when compared with Arm 3 (P = .02, P = .003, respectively), and there was no statistically significant difference between Arm 1 and Arm 2 (P = .93, P = .13, respectively) ( Figure 3 ).
Univariable and Multivariable Analysis of Predictors of Survival
The results of univariable survival analysis are listed in Table 1 . In multivariable analysis, independent risk factors of survival were treatment allocation Arm 1 vs Arm 3 (hazard ratio [HR] =1.80, 95% CI = 1.35 to 2.39; P < .001), treatment allocation Arm 1 vs Arm 2 (HR = 1.21, 95% CI = 0.91 to 1.61; P = .20), age (HR = 0.98, 95% CI = 0.97 to 1.00; P = .003), neutrophil:lymphocyte ratio (HR = 1.12, 95% CI = 1.06 to 1.19; P < .001), serum albumin (HR = 0.95, 95% CI = 0.93 to 0.98; P < 0.001), total bilirubin (HR = 1.02, 95% * Arm 1 = three-drug chemolipiodolization with embolization; Arm 2 = three-drug chemolipiodolization without embolization; Arm 3 = single-drug chemolipiodolization with embolization; CI = confidence interval † Two sided P-value was calculated after covariable adjustment by multivariable Cox proportional-hazards analysis. ‡ P value was calculated by a two-sided χ 2 test. § There were 22 patients who could not be evaluated for treatment response because of death, poor performance status, or patients' refusal of computed tomography scan at 6 weeks. * Arm 1 = three-drug chemolipiodolization with embolization; Arm 2 = three-drug chemolipiodolization without embolization; Arm 3 = single-drug chemolipiodolization with embolization. † P value was calculated by a two-sided χ 2 test. ‡ Postembolization syndrome or blood change or liver function change might include more than one complication item.
Downloaded from https://academic.oup.com/jnci/article-abstract/105/1/59/877633 by guest on 26 January 2019 CI = 1.01 to 1.03; P < .001), alpha-fetoprotein (HR = 1.46, 95% CI = 1.13 to 1.90; P = .004), and BCLC stage (HR = 2.07, 95% CI = 1.62 to 2.64; P < .001).
Discussion
In this study, patients in Arm 1 and Arm 3 had median survivals of 10.5 and 5.9 months, respectively. Triple-drug chemolipiodolization with embolization statistically significantly improved tumor response and survival when compared with a single-drug chemolipiodolization with embolization in patients either with intermediate or advanced HCC. Treatment allocation was identified as an independent prognostic predictor, further confirming the benefits of triple-drug chemolipiodolization. These results show that the chemotherapeutic agents played an important role in the survival advantage of TACE and might also be valuable for other transarterial therapies. It is well known that drug-eluting beads have a great advantage by offering simultaneous embolization and sustained release of chemotherapeutic agents in a controlled manner (24, 25) . However, beads were commonly loaded with single-agent doxorubicin in previous studies. It might be valuable to study the efficacy and safety of beads loaded with multiple chemotherapeutic agents. Furthermore, radioembolization is another kind of transarterial therapy, which can deliver high doses of radiation inside the tumor. Because many studies have shown that radioembolization is effective and safe (26, 27) , it might be valuable to evaluate the feasibility of radioembolization combined with chemolipiodolization or beads loaded with chemotherapeutic agents. It should be noted that Sahara et al. recently reported a randomized trial that failed to show survival differences between 24 patients who received TACE with multiple drugs and 27 patients who received single-agent epirubicin (28) . However, the sample size might not have been large enough.
The impact on survival of adding embolization to the treatment of patients given transarterial chemotherapy also remains largely controversial. One randomized trial published in 1995 showed a statistically significant survival advantage of gelatin-sponge embolization (29) . However, all three recent randomized trials failed to show survival differences between transarterial chemotherapy with or without embolization (8) (9) (10) . In our study, the difference in overall survival between Arm 1 and Arm 2 was also small and not statistically significant (median survival = 10.5 vs 10.1 months), although patients in Arm 1 achieved more objective responses than those in Arm 2 (P = .009). These results suggest that removal of embolization from chemoembolization might not statistically significantly decrease survival and triple-drug chemolipiodolization without embolization might be a good therapeutic option for treating HCC patients with poor hepatic reserve or major portal vein occlusion by tumor thrombosis.
In this trial, the incidence of major complications was not statistically significantly different among all three arms, and all TACErelated complications were adequately managed using nonoperative treatment, except for one death associated with the TACE procedure. These results suggest that the three TACE regimens are safe.
The overall median survival among participants in our study appeared to be less satisfactory compared with results from previous studies (16) because this trial enrolled patients with more advanced tumors than most previous studies: only patients with HCC larger than 7 cm were included, most well-encapsulated HCCs were excluded from this study because surgeons thought they were still resectable, and 34.5% of included patients had portal vein tumor thrombosis. It is reasonable that we set such inclusion criteria, although sorafenib was recommended as the standard care for patients with HCC and portal vein tumor thrombosis. To date, developing countries account for 85% of all HCCs that occur globally (30) . There is a need to develop effective treatments for HCC with portal vein tumor thrombosis in settings where sorafenib is not feasible at the population level. Furthermore, in previous studies, our group and a Korean group demonstrated that these patients were still good candidates for TACE (17, 31) . Also, if the trial had included patients with less-advanced HCC, a considerable number of patients might have been downstaged to undergo curative treatment (32) . The survival of these patients would be largely influenced by the choice of subsequent resection or ablation, options of resection margin, and so on (33) .
One limitation of this study is its single-blind nature. The treating oncologist needed to be informed about the actual regiment to report and treat toxicity. However, this was unlikely to influence the patient's overall survival, which is the objective primary endpoint of the trial, and the sample size of this study was large enough to make an important contribution to the available literature. The second limitation is that the subsequent treatments for patients who had stopped study TACE might be influenced by investigator and patient decisions. Also, the subsequent treatment in Arm 1 was more active than in Arm 3. However, this can be explained by the better treatment response in the former because the subsequent treatments depended mostly on tumor burden and liver function. The third limitation was that the gelatin sponge particles used in this study might be too large and cause only temporary thrombosis. The small particle size of polyvinyl alcohol may be a more permanent and effective choice (12) . A) Stage B HCC patients. Survival in Arm 1 (triple-drug chemolipiodolization with embolization) was statistically significantly higher than that in Arm 3 (single-drug chemolipiodolization with embolization) (P = .02), whereas there was no difference between Arm 1 and Arm 2 (triple-drug chemolipiodolization without embolization) (P = .93). B) Stage C HCC patients. Survival in Arm 1 was statistically significantly higher than that in Arm 3 (P = .003), whereas there was no difference between Arm 1 and Arm 2 (P = .13). 
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